Delcath Systems (NASDAQ:DCTH) Releases Earnings Results, Beats Expectations By $0.19 EPS

Delcath Systems (NASDAQ:DCTH) released its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19, RTT News reports. The business had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative return on equity of 1,007.65% and a negative net margin of 2,308.86%. During the same quarter in the prior year, the company posted ($0.86) earnings per share.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $5.09 on Thursday. Delcath Systems has a 52-week low of $2.25 and a 52-week high of $7.99. The firm has a 50-day moving average of $4.34 and a 200-day moving average of $3.84. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.11 and a current ratio of 3.30.

Insider Buying and Selling at Delcath Systems

In other news, Director Gil Aharon acquired 26,882 shares of Delcath Systems stock in a transaction dated Tuesday, March 19th. The stock was bought at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now directly owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 21.10% of the company’s stock.

Hedge Funds Weigh In On Delcath Systems

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Delcath Systems by 19.7% in the fourth quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock valued at $2,172,000 after purchasing an additional 85,948 shares in the last quarter. Geode Capital Management LLC raised its stake in Delcath Systems by 85.8% during the second quarter. Geode Capital Management LLC now owns 116,536 shares of the company’s stock worth $679,000 after acquiring an additional 53,803 shares in the last quarter. Cibc World Market Inc. lifted its holdings in shares of Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after acquiring an additional 3,432 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Delcath Systems by 82.7% in the 4th quarter. Northern Trust Corp now owns 60,667 shares of the company’s stock valued at $252,000 after purchasing an additional 27,458 shares in the last quarter. Finally, BlackRock Inc. increased its position in Delcath Systems by 183.7% during the 2nd quarter. BlackRock Inc. now owns 47,180 shares of the company’s stock worth $275,000 after purchasing an additional 30,548 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. StockNews.com raised Delcath Systems to a “sell” rating in a report on Wednesday. HC Wainwright boosted their price objective on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.